In This Issue/Research Watch/News-in-Brief/News from the IASLC Tobacco Control Committee
The Journal of Thoracic Oncology Achieves a New Benchmark
Local Therapy for Pulmonary Oligometastases: Is SABR a New Champion?
Optimal Treatment of Stage IIIA-N2 Non–Small Cell Lung Cancer: A Neverending Story?
Fast, Food and Ceritinib in ALK-Positive NSCLC
Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase ( ALK )-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R
Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung Cancer
Comprehensive Analysis of EGFR -Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations
Management of Multifocal Lung Cancer: Results of a Survey
Clinical and Pathological Staging Validation in the Eighth Edition of the TNM Classification for Lung Cancer: Correlation between Solid Size on Thin-Section Computed Tomography and Invasive Size in Pathological Findings in the New T Classification
Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non–Small Cell Lung Cancer: NRG Oncology RTOG 0839
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
Resectable Clinical N2 Non–Small Cell Lung Cancer; What Is the Optimal Treatment Strategy? An Update by the British Thoracic Society Lung Cancer Specialist Advisory Group
Long-term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligometastases
Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer
Histologic Transformation in NSCLC with PD-1 therapy
Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung
Prophylactic Cranial Irradiation in Resected Small Cell Lung Cancer: Comprehensive Staging, Adjuvant Chemotherapy, and Strict Stratification of Pathological Stage Play a Role
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
Atypical Pleuropulmonary Tuberculosis Mimicking a Malignant Disease
To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non–Small Cell Lung Cancer and Psoriasis
The Influence of Body Mass Index on Overall Survival following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues
Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues”
More Health Outcomes Analysis from More Representative Population Data Is Necessary prior to Bronchial Genomic Classifier Application in Real Practice
Response to Lee et al.